Login / Signup

Severe type I interferonopathy and unrestrained interferon signaling due to a homozygous germline mutation in STAT2.

Christopher James Arthur DuncanBenjamin J ThompsonRui ChenGillian I RiceFlorian GotheDan F YoungSimon C LovellVictoria G ShuttleworthVicky BrocklebankBronte CornerAndrew J SkeltonVincent BondetJonathan CoxheadDarragh DuffyCecile FourrageJohn H LivingstonJulija PavaineEdmund CheesmanStephania BitettiAngela GraingerMeghan AcresBarbara A InnesAneta MikulasovaRuyue SunRafiqul HussainRonnie WrightRobert WynnMohammed ZarhrateLeo A H ZeefKatrina WoodStephen M HughesClaire Louise HarrisKarin R EngelhardtYanick J CrowRichard E RandallDavid KavanaghSophie HambletonTracy A Briggs
Published in: Science immunology (2020)
Excessive type I interferon (IFNα/β) activity is implicated in a spectrum of human disease, yet its direct role remains to be conclusively proven. We investigated two siblings with severe early-onset autoinflammatory disease and an elevated IFN signature. Whole-exome sequencing revealed a shared homozygous missense Arg148Trp variant in STAT2, a transcription factor that functions exclusively downstream of innate IFNs. Cells bearing STAT2R148W in homozygosity (but not heterozygosity) were hypersensitive to IFNα/β, which manifest as prolonged Janus kinase-signal transducers and activators of transcription (STAT) signaling and transcriptional activation. We show that this gain of IFN activity results from the failure of mutant STAT2R148W to interact with ubiquitin-specific protease 18, a key STAT2-dependent negative regulator of IFNα/β signaling. These observations reveal an essential in vivo function of STAT2 in the regulation of human IFNα/β signaling, providing concrete evidence of the serious pathological consequences of unrestrained IFNα/β activity and supporting efforts to target this pathway therapeutically in IFN-associated disease.
Keyphrases